ide196
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Jul 31, 2019 (NCT03947385)
Timeline
Indications
Mechanism of action
- Protein kinase C alphaINHIBITOR
PRKCA inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1(N)CCN(c2cccnc2NC(=O)c2nc(-c3ncccc3C(F)(F)F)cnc2N)CC1- Mol. weight
- 472.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3982723 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07015190 | Phase 3 | Oct 31, 2025 | IDEAYA Biosciences |
| NCT05987332 | Phase 2/Phase 3 (Phase 3) | Oct 31, 2023 | IDEAYA Biosciences |
| NCT05907954 | Phase 2 | Jul 3, 2023 | IDEAYA Biosciences |
| NCT05187884 | Phase 2 | May 3, 2022 | University of New South Wales |
| NCT03947385 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2019 | IDEAYA Biosciences |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IDEAYA Biosciences | For profit | 4 | 4 | 2 | 2019 |
| University of New South Wales | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1